TransMedics Group is trading 10% up at $88.80 in after-hours trading after reporting second-quarter 2026 results that surpassed top-line estimates.
- Revenue reached $189.9 million, exceeding analyst expectations and prompting the company to raise the low end of its full-year 2026 revenue guidance.
- The strong revenue performance and improved outlook helped offset investor concerns regarding an EPS miss driven by higher-than-expected operating costs.
- While a broader market risk-on tone is supportive, the price action is primarily attributed to the positive earnings report and guidance update.